Google
DMAC 株価分析 — Diamedica Therapeutics Inc (Healthcare >> Biotechnology)
DMAC に関するよくある質問
DMACのROE（自己資本利益率）は？
Diamedica Therapeutics IncのROEは-74.31%です。
DMACの配当利回りは？
Diamedica Therapeutics Incの配当利回りは0.00%です。
DMACの品質スコア（Quality Score）は？
当社のAIはDMACの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
DMACは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
DMACはどのセクターに属しますか？
Diamedica Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
DMAC AI Analysis Summary
Our AI summary for DMAC: Diamedica Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -74.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.54
Price
0.02
(0.31%)
Day Change
|
|
|---|
DMAC, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.54 |
| PBV / Sector |
7.44 / 44,022.72
|
| Earning Per Share | -0.65 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
1.29 M
GREAT
|
| Average 1W Daily Value |
1.27 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
68% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:05 |
| Symbol | DMAC |
| Name | DIAMEDICA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 53.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 351.32 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 301 Carlson Parkway, Minneapolis, MN, United States, 55305
Phone: 763 496 5454
Website: https://www.diamedica.com
Sector: Healthcare >> Biotechnology
Description: DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
